Loading...

PE anti-mouse Ly-6C Antibody

Pricing & Availability
Clone
HK1.4 (See other available formats)
Regulatory Status
RUO
Other Names
Lymphocyte antigen 6 complex, locus C
Isotype
Rat IgG2c, κ
Ave. Rating
Submit a Review
Product Citations
publications
HK1dot4_PE_040111
C57BL/6 bone marrow cells were stained with Ly-6C (clone HK1.4) PE (filled histogram), or rat IgG2c, κ PE isotype control (open histogram). Gated on myeloid cell population.
  • HK1dot4_PE_040111
    C57BL/6 bone marrow cells were stained with Ly-6C (clone HK1.4) PE (filled histogram), or rat IgG2c, κ PE isotype control (open histogram). Gated on myeloid cell population.
Compare all formats See PE spectral data
Cat # Size Price Save
128007 50 µg ¥29,480
128008 200 µg ¥73,700
Description

Most hematopoietic cells express one or more members of Ly-6 family. The expression of Ly-6 varies with development stage and activation. Ly-6C is a 14-17 kD GPI-linked surface protein expressed on mouse monocyte/macrophage cells, endothelial cells, neutrophils, and some T cell subsets. Ly-6C is reported to be an indicator of memory CD8+ T cells.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
L3 cloned CTL cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone HK1.4 does not block the binding of clone RB6-8C58.

Additional reported applications (for relevant formats of this clone) include: in vitro activation of T cells1-3 and immunohistochemistry of frozen sections4.

Application References

(PubMed link indicates BioLegend citation)
  1. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (Activ)
  2. Herold KC, et al. 1990. Diabetes 39:815. (Activ)
  3. Havran WL, et al. 1988. J. Immunol. 140:1034 (Activ)
  4. Flanagan K, et al. 2008. J. Immunol. 180:3874. (IHC)
  5. Makaroff LE, et al. 2009. P. Natl. Acad. Sci. USA 106:4799. (FC)
  6. Zuber J, et al. 2009. Genes Dev. 23:877. (FC) PubMed
  7. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
  8. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
  9. Watson NB, et al. 2015. J Immunol. 194:2796. PubMed
Product Citations
  1. Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed
  2. Melo-Silva CR, et al. 2022. Cell Rep. 41:111676. PubMed
  3. Wu Z, et al. 2023. EMBO Rep. 24:e56524. PubMed
  4. Guan H, et al. 2023. Int J Mol Sci. 24:. PubMed
  5. Pioli KT, et al. 2023. iScience. 26:106223. PubMed
  6. Tang C, et al. 2023. Nat Commun. 14:1493. PubMed
  7. Yao H, et al. 2023. Front Immunol. 14:1147674. PubMed
  8. Kim BH, et al. 2023. Sci Rep. 13:6577. PubMed
  9. Denny L, et al. 2021. Clin Transl Immunology. 10:e1234. PubMed
  10. Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed
  11. Jauch-Speer SL, et al. 2022. Elife. 11: . PubMed
  12. Dong H, et al. 2022. Proc Natl Acad Sci U S A. 119:e2123247119. PubMed
  13. Zheng Z, et al. 2022. Cells. 11: . PubMed
  14. An HW, et al. 2022. Cell Rep. 41:111878. PubMed
  15. Cheng P, et al. 2023. Pharmacol Res. 188:106643. PubMed
  16. Petersen B, et al. 2014. J Leukoc Biol. 95:809. PubMed
  17. Zuchtriegel G, et al. 2016. PLoS Biol. 14: 1002459. PubMed
  18. Zhou W, et al. 2019. Cell Syst. 0.597916667. PubMed
  19. Fu R, et al. 2020. Sci Rep. 10:1455. PubMed
  20. Tan L, et al. 2022. Biochem Biophys Rep. 32:101351. PubMed
  21. Gerwing M, et al. 2020. Mol Imaging Biol. 1.959027778. PubMed
  22. Zhang YS, et al. 2018. Cancer Biol Ther. 19:735. PubMed
  23. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  24. Jiang W, et al. 2021. Oncol Lett. 22:625. PubMed
  25. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  26. Huai W, et al. 2019. J Exp Med. 216:772. PubMed
  27. Zou L, et al. 2022. Brain Behav Immun. 100:10. PubMed
  28. Chen WS, et al. 2021. Cell Rep. 37:109974. PubMed
  29. Park JG, et al. 2021. iScience. 24(9):102941. PubMed
  30. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  31. Davis FM, et al. 2019. Arterioscler Thromb Vasc Biol. 39:2353. PubMed
  32. Cai B, et al. 2021. Mol Cancer. 20:165. PubMed
  33. Molina-Sanchez P, et al. 2020. Gastroenterology. 2203:159. PubMed
  34. Nguyen CM, et al. 2019. Diabetes. 68:1499. PubMed
  35. Dieterich LC, et al. 2019. International Journal of Cancer. 145(10):2804-2815. PubMed
  36. Fachi JL, et al. 2020. J Exp Med. 217:00:00. PubMed
  37. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  38. Gui J, et al. 2020. Nat Cancer. 1:603. PubMed
  39. Yu X, et al. 2022. J Extracell Vesicles. 11:e12185. PubMed
  40. Yoshida K, et al. 2022. Sci Rep. 12:17276. PubMed
  41. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  42. Wang F, et al. 2018. Carcinogenesis. 39:889. PubMed
  43. Sun KT, et al. 2018. Front Physiol. 1.06875. PubMed
  44. Francis M, et al. 2017. Toxicol Sci. 155(1):182-195. PubMed
  45. Zuber J, et al. 2009. Genes Dev. 1.567361111. PubMed
  46. Mishra BB, et al. 2017. Nat Microbiol. 2:17072. PubMed
  47. Zuo W, et al. 2022. Cell Death Discov. 8:257. PubMed
  48. Gousopoulos E, et al. 2016. Am J Pathol. 186:2193-2203. PubMed
  49. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  50. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
  51. Burns JC, et al. 2020. eLife. 9:00. PubMed
  52. Guldner IH, et al. 2020. Cell. 183(5):1234-1248.e25. PubMed
  53. Liu Z, et al. 2021. Immunity. 54(2):247-258.e7. PubMed
  54. Deerhake ME, et al. 2021. Immunity. 54(3):484-498.e8. PubMed
  55. De Simone G, et al. 2021. Immunity. :. PubMed
  56. Guichard V, et al. 2017. Elife. 6:e27215. PubMed
  57. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  58. Monaghan KL, et al. 2020. J Vis Exp. . PubMed
  59. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  60. Kar S, Colino J, Snapper C 2016. J Immunol. 196: 4204 - 4213. PubMed
  61. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
  62. Winchell CG, et al. 2020. Front Immunol. 1.077083333. PubMed
  63. Takaku S, et al. 2022. Evid Based Complement Alternat Med. 2022:6122955. PubMed
  64. Chen ST et al. 2019. Cell host & microbe. 25(4):602-616 . PubMed
  65. Miyamoto T, et al. 2021. Cancer Immunol Res. Online ahead of print. PubMed
  66. Franklin DA, et al. 2020. JCI Insight. 5:. PubMed
  67. Kitamura K, et al. 2019. Int J Cardiol Heart Vasc. 23:100344. PubMed
  68. Zhu K, et al. 2022. EMBO Rep. 23:e54499. PubMed
  69. Hakim R, et al. 2021. J Neurosci. 41:8441. PubMed
  70. Gu H, et al. 2021. Elife. 10:. PubMed
  71. Chen C, et al. 2020. Cell Rep. 2136:30. PubMed
  72. Yurdagul A Jr, et al. 2020. Cell Metabolism. 31(3):518-533.e10. PubMed
  73. Ireland L, et al. 2020. Front Immunol. 11:297. PubMed
  74. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  75. Tang W, et al. 2021. Exp Ther Med. 22:1483. PubMed
  76. Gong P, et al. 2022. Cell Death Discov. 8:466. PubMed
  77. White JP et al. 2018. Cell. 175(5):1198-1212 . PubMed
  78. Wang X, et al. 2021. Theranostics. 11:209. PubMed
  79. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  80. Chen J, et al. 2014. Cell Res. 24:1050. PubMed
  81. Moreno M et al. 2014. The Journal of Neuroscience. 34(24):8175-85 . PubMed
  82. Wang Y, et al. 2020. Immunity. 53(6):1168-1181.e7. PubMed
  83. Yáñez A et al. 2017. Immunity. 47(5):890-902 . PubMed
  84. Riopel M, et al. 2019. Mol Metab. 20:89. PubMed
  85. Aggarwal N, et al. 2021. Cell Rep. 37:110170. PubMed
  86. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  87. Hohsfield LA, et al. 2021. Elife. 10:. PubMed
  88. Ren X, et al. 2021. Cell Death Dis. 12:484. PubMed
  89. Francis M, et al. 2016. Toxicol Sci. 10.1093/toxsci/kfw226. PubMed
  90. Denk F, et al. 2016. Cell Rep. 15: 1771-1781. PubMed
  91. Koronyo Y, et al. 2015. Brain. 138: 2399-2422. PubMed
  92. Younos I, et al. 2011. Int Immunopharmacol. 11:816. PubMed
RRID
AB_1186132 (BioLegend Cat. No. 128007)
AB_1186132 (BioLegend Cat. No. 128008)

Antigen Details

Structure
14-17 kD protein (134 amino acids), member of the Ly-6 family of GPI linked protein. Ly6 family members share structure homology throughout a distinctive cystein rich protein domain that incorporates O-linked carbohydrates.
Distribution

Ly-6C is expressed primarily on bone marrow myeloid populations, monocytes/macrophages, neutrophils, endothelial cells, and some T cell subsets. Ly-6C is also a marker of memory CD8+ T cells.

Cell Type
Endothelial cells, Macrophages, Monocytes, Neutrophils, T cells
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
2. Cerwenka A, et al. 1998. J. Immunol. 161:97.

Gene ID
17067 View all products for this Gene ID
UniProt
View information about Ly-6C on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 2    Revision Date: 12/09/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account